New Delhi, Dec 6: Hyperbaric Oxygen treatment might be a possible cure for the symptoms Alzheimer’s disease, claim the researchers of American Friends of Tel Aviv University in New York. The therapy is provided to patients with neurological problems. The patients under this treatment are made to breathe in a confined chamber containing pure oxygen where the air pressure is twice more than the normal.
The report states that there is an increase in the oxygen solubility in blood due to this therapy which circulates throughout the body through the blood vessels. With an increase in the oxygen levels in blood, the growth factors and stem cells of the body are enhanced which gives a boost to the health of the patient.
The research was published in a journal named “Neurobiology of Aging” and the study was led by Prof Uri Ashery from TAU’s Sagol School of Neuroscience and Faculty of Life Sciences. “This revolutionary treatment for Alzheimer’s disease uses a hyperbaric oxygen chamber, which has been shown in the past to be extremely effective in treating wounds that were slow to heal,” said Prof Ashery in the report.
The initial test of the study was conducted on mice. The researchers established a mouse model of Alzheimer’s disease and built a suitable hyperbaric oxygen chamber accordingly. They observed the mice undergo the treatment for one hour per day for 14 days. Later, behavioral and tissue biochemical tests were conducted on these animals to ensure results of the therapy on the pathology of Alzheimer’s disease.
“In this hallmark study, the beneficial physiological effects of hyperbaric oxygen therapy were directly demonstrated on Alzheimer-affected brain tissue,” said Prof. Shai Efrati from TAU’s Sackler Faculty of Medicines who also contributed to the research. The study claims that behavioral deficiencies have reduced. There has been a 40 per cent decline in plaque pathology and neuroinflammation, respectively.
The study was conducted by Ronit Shapira, a Ph.D. student of TAU’s Faculty of Life Sciences under the guidance of Prof Ashery, Prof Efrati, Prof Beka Solomon and Dan Frankel from TAU’s School of Neuroscience and Faculty of Life Sciences.